Focus: Conception is a Berkeley-based biotechnology company specializing in cell conversion technology focused on reproductive medicine and women's health applications. The company operates as a public-stage biotech with a narrow but innovative therapeutic focus.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
High-risk, high-reward early-stage biotech best suited for scientists seeking foundational cell therapy innovation opportunities, but limited hiring and unclear financial health warrant thorough diligence before commitment.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Conception
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Conception's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Progyny, Inc. (PGNY) (CIK 0001551306) — EX-99.1
EX-99.1
8-K Filing: AUDIOEYE INC (AEYE) (CIK 0001362190) — EXHIBIT 10.1
EXHIBIT 10.1
8-K Filing: ARTIVION, INC. (AORT) (CIK 0000784199) — EX-10.1
EX-10.1
8-K Filing: Birchtech Corp. (BCHT) (CIK 0000728385) — AMENDED AND RESTATED EMPLOYMENT AGREEMENT
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
8-K Filing: TruGolf Holdings, Inc. (TRUG) (CIK 0001857086) — EX-10.1
EX-10.1
8-K Filing: B&G Foods, Inc. (BGS) (CIK 0001278027) — EXHIBIT 10.2 - ANDREW D. VOGEL EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 3, 2022
EXHIBIT 10.2 - ANDREW D. VOGEL EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 3, 2022
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo